Robert Risinger, MD

  • 4Articles
  • 42.9KReads1
  • 2015–2022Active
  • 24Collaborators
  • 166Citations2

About

Robert Risinger, MD, is affiliated with BioXcel Therapeutics, Inc. in New Haven, Connecticut. His publications from 2015 to 2022 focus on schizophrenia and schizoaffective disorders, specifically investigating treatments such as sublingual dexmedetomidine and aripiprazole lauroxil. His research includes clinical trials assessing therapeutic response durability, metabolic and endocrine effects, and safety considerations in acute schizophrenia episodes. Risinger has frequently collaborated with co-authors including Yangchun Du, Anjana Bose, Bernard L. Silverman, Elliot W. Ehrich, and Henry A. Nasrallah.

Publications

JCP
Sublingual Dexmedetomidine for Agitation in Schizophrenia
Original Research

Sublingual Dexmedetomidine for Agitation in Schizophrenia

October 3, 2022

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or schizoaffective disorder.
, , , et al
JCP
Original Research

Therapeutic Durability of Aripiprazole Lauroxil

September 19, 2017

Injectable antipsychotics can help address the problem of nonadherence, which can lead to relapse. This study looks at the efficacy of the injectable antipsychotic aripiprazole lauroxil in achieving and...
, , , et al
JCP
Original Research

Metabolic Effects of Aripiprazole Lauroxil

November 23, 2016

Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating schizophrenia symptoms in a recent RCT. But how does it stack up against other antipsychotics in terms...
, , , et al
JCP
Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

August 26, 2015

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe